New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:06 EDTISISIsis Pharmaceuticals' ISIS-GCGR for diabetes shows positive Phase 2 results
Isis Pharmaceuticals announced positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy. In this study, patients in the per protocol efficacy population treated with ISIS-GCGRRx achieved statistically significant reductions in measures of glucose control. Patients treated with ISIS-GCGRRx also experienced increased plasma GLP-1 levels.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
07:06 EDTISISIsis Pharmaceuticals initiates phase 1/2 study of ISIS-DMPK Rx
Subscribe for More Information
December 11, 2014
09:28 EDTISISIsis Pharmaceuticals up 3% after CEO appears on Mad Money
Subscribe for More Information
December 8, 2014
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use